Dr. Julie Lemieux is a hemato-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Lemieux is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Lemieux is a member of the Canadian Clinical Trial Group for quality of life in breast cancer. She is also a scientific committee member for the McPeak-Sirois research group.

Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and monitoring of cancers and benign breast diseases.

Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
J0-14
Québec, Québec
Canada G1S 4L8
63 entries « 1 of 7 »

Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA,

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Journal Article

Breast Cancer Res Treat, 204 (2), 2024.

Abstract | Links:

Assan O, Memoli V, Guillaumie L, Turcotte V, Lemay M, Dionne A, Lemieux J, Provencher L, Gotay C, de Bruin M, Guénette L, Lauzier S

Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results

Journal Article

J Cancer Surviv, 2024.

Abstract | Links:

Thériault K, Ben Moussa M, Perron M, Desbiens C, Poirier B, Poirier É, Leblanc D, Morin C, Lemieux J, Hogue JC, Boudreau D

A Single-Center 18-Year Series of 73 Cases of Metaplastic Carcinoma of the Breast

Journal Article

Breast J, 2024 , 2024.

Abstract | Links:

Mc Brearty C, Bisaillon L, Dorval M, Nabi H, Desbiens C, Lemieux J, Théberge V, Baghdadli A, Lauzier S, Savard J

Disruptions in Cancer Care Due to the COVID-19 Pandemic and Fear of Cancer Recurrence in Women with Breast Cancer: A Mixed-Methods Study

Journal Article

Curr Oncol, 31 (2), 2024.

Abstract | Links:

Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer

Journal Article

J Clin Oncol, 41 (35), 2023.

Abstract | Links:

Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, Marwick TH

Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial

Journal Article

JACC Cardiovasc Imaging, 16 (3), 2023.

Abstract | Links:

Audet S, Doyle C, Lemieux C, Tardif MA, Gauvreau A, Simonyan D, Nabi H, Lemieux J

Adherence to CONSORT Guidelines and Reporting of the Determinants of External Validity in Clinical Oncology Randomized Controlled Trials: A Review of Trials Published in Four Major Journals between 2013 and 2015

Journal Article

Curr Oncol, 30 (2), 2023.

Abstract | Links:

Schmid P, Cortes J, Joaquim A, Jañez NM, Morales S, Díaz-Redondo T, Blau S, Neven P, Lemieux J, García-Sáenz JÁ, Hart L, Biyukov T, Baktash N, Massey D, Burris HA, Rugo HS

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

Journal Article

Breast Cancer Res, 25 (1), 2023.

Abstract | Links:

Hershman DL, Chen BE, Sathe C, Parulekar WR, Lemieux J, Ligibel JA, Gelmon KA, Whelan TJ, Goodwin PJ

Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)

Journal Article

Breast Cancer Res Treat, 200 (1), 2023.

Abstract | Links:

Simmons C, Rayson D, Joy AA, Henning JW, Lemieux J, McArthur H, Card PB, Dent R, Brezden-Masley C

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

Journal Article

Ther Adv Med Oncol, 14 , 2022.

Abstract | Links:

63 entries « 1 of 7 »
Signaler des ajouts ou des modifications

Active projects

  • Age-related patterns in the experience of chemotherapy-induced peripheral neuropathy, from 2019-10-01 to 2024-09-30
  • Elucidating patient and healthcare practitioner decision-making about chemotherapy-induced peripheral neuropathy-related, from 2023-04-01 to 2027-03-31
  • Favoriser l'engagement des femmes ayant eu un cancer du sein dans les décisions concernant l'hormonothérapie adjuvante prolongée, from 2023-10-01 to 2027-05-31
  • NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
  • PALbociclib CoLlaborative Adjuvant Study (PALLAS study), from 2017-05-17 to 2025-12-25
  • Personalized risk-stratified breast cancer follow-up care: a feasibility and acceptability study, from 2023-06-26 to 2026-06-30
  • Pour des soins en oncologie inclusifs: Améliorer le parcours et l'expérience de soins des personnes des minorités sexuelles et de genre, from 2023-12-13 to 2025-12-12
  • The effect of cannabinoid receptors on breast cancer survival, from 2022-09-01 to 2025-08-31
  • Une infrastructure IA multi-usagers clé en main pour gérer le cycle de vie complet des données en santé, from 2021-04-01 to 2024-06-30
  • Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, from 2023-04-01 to 2025-03-31

Recently finished projects

  • Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
  • Perfectionism and psychosocial adjustment to cancer : A mixed methods study, from 2020-03-31 to 2024-03-31
  • Projet pilote de l'utilisation d'une application pour le suivi et la prise en charge des effets secondaires associés aux traitements anti-néoplasiques oraux chez les patientes avec cancer du sein, from 2021-08-01 to 2023-07-31
  • TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2024-02-29
Data provided by the Université Laval research projects registery